Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

FIRST BIO GENETICS LLC

NPI: 1073398723 · MESA, AZ 85210 · Clinical Medical Laboratory · NPI assigned 08/30/2023

$847K
Total Medicaid Paid
25,363
Total Claims
9,514
Beneficiary Records
9
Codes Billed
2023-08
First Month
2024-12
Last Month

Provider Details

Authorized OfficialDASS, SATISH (CEO)
NPI Enumeration Date08/30/2023

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2023 2,424 $265K
2024 22,939 $582K

Billing Codes

CodeDescriptionClaimsBene. RecordsTotal Paid
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 8,428 2,576 $432K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 10,631 3,141 $252K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 2,160 723 $146K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 1,319 490 $5K
84443 Thyroid stimulating hormone (TSH) 798 762 $4K
80053 Comprehensive metabolic panel 899 858 $3K
85027 899 861 $2K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 12 12 $2K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV 217 91 $1K